FDA approves Lumicell’s breast cancer imaging tool
Lumicell developed the technology to enable physicians to detect residual cancer in the breast cavity after surgery.
MassDevice5d
FDA approves Lumicell’s breast cancer visualization system
Lumicell today announced it received FDA approval for its LumiSystem direct visualization system for breast cancer removal.
Monthly Prescribing Reference6d
FDA Approves Drug-Device Combo to Detect Residual Cancer After Lumpectomy
Approval was supported by data from a randomized, intra-patient controlled trial, which included patients with confirmed invasive breast cancer, ductal carcinoma in situ, or both. The Food and Drug ...
healthandpharma2d
FDA Approves New Imaging System to Enhance Tumor Detection in Breast Cancer Surgeries
FDA has approved Lumicell's LumiSystem, a combination of a fluorescent imaging drug Lumisight and a visualization device, to ...
Alzheimer's drug embrace slows down as US doctors' reluctance grows
The adoption of the FDA-approved Alzheimer's drug, Leqimbi, has slowed down in the U.S. as more experts grow hesitant about ...
FierceBiotech4d
FDA approves Lumicell’s fluorescent system for highlighting residual breast cancer tissue
The FDA has granted a groundbreaking approval to a fluorescent light system that illuminates leftover breast cancer tissue in ...
Cancer Therapy Advisor4d
FDA Approves Lumisight to Detect Residual Cancer After Lumpectomy
The US Food and Drug Administration (FDA) has approved Lumisight (pegulicianine), a fluorescent imaging agent, for use in adults with breast cancer to aid in intraoperative detection of cancerous ...
Morningstar5d
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
According to the FDA, collaboration among international regulators may allow patients with cancer to receive earlier ... It is not known if Alecensa passes into breast milk. A patient should ...
Seeking Alpha5d
FDA approves Roche's Alecensa for early stage ALK+ lung cancer
The FDA has approved Roche’s Alecensa for the treatment of early stage resected non-small cell lung cancer, or NSCLC ... to remove their tumors. The drug was developed by Roche’s Genentech ...
Business Insider4d
FDA Approves Genentech's Alecensa For ALK-positive Early-Stage Lung Cancer
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), said that the U.S. Food and Drug Administration ... lung cancer or NSCLC (tumors 4 cm or node positive), as detected by an FDA-approved ...